The same criterion of Cmax in China now [Study As­sess­ment]

posted by wxp  – China, 2013-05-28 08:10 (4367 d 16:27 ago) – Posting: # 10670
Views: 13,627

Hi, Shuanghe and Helmut,

❝ ❝ From the Xipei's habit of estimating sample size with AUC I assume this is a study for Chinese regulation. If so, the Chinese BE guideline reads that criterion for AUC is 80-125 but for Cmax, hold-on, deep breath, …, 70-143% (and the study doesn't even have to be of replicate design :-D)


❝ Oh wow! With such limits AUC is really the win-loose-metric. Are you referring to the 2005 GL?

等效判断标准,一般规定,经对数转换后的受试制剂的AUC0→t 在参比 制剂的80%-125%范围,受试制剂的Cmax 在参比制剂的70%-143%范围。


The Chinese criteria of Cmax changed in 2010 to 75%~133% according to the latest guideline (Appendix XIXB in Chinese Pharmacopoeia (version 2010)). The criteria of AUC is still 80%~125%.

Helmut, it really surprised me that you can read Chinese.

❝ Well, hundreds of products were approved in the EU with those limits – but decades ago…


Chinese regulation improved these years, but there is still no specific guidelines on the BE of HVD. However,Chinese experts are very interested in it.

P.S. Chinese FDA changed the name to China Food and Drug Administration (CFDA) :-D

Best regards,

Xipei
China

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
78 visitors (0 registered, 78 guests [including 38 identified bots]).
Forum time: 00:38 CEST (Europe/Vienna)

If you shut your door to all errors
truth will be shut out.    Rabindranath Tagore

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5